Susan B Laffan (Susan Laffan)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 4

Top Topics

Hiv Infected Patients

Randomized Controlled Trial

Preterm Infants

Top Venues

Birth defects research

Disease models & mechanisms

GlaxoSmithKline Research and Development

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GlaxoSmithKline Research and Development

United States

Sr. Director/Global Head Investiative Toxicology :: Non-Clinical Safety

Publications

Sarah N Campion, Amy Inselman, Belinda Hayes, Costanza Casiraghi, David Joseph, Fabrizio Facchinetti, Fabrizio Salomone, Georg Schmitt, Julia Hui, Karen Davis-Bruno, Karen Van Malderen, LaRonda Morford, Luc De Schaepdrijver, Lutz Wiesner, Stephanie Kourula, Suna Seo, Susan B Laffan, Vijay Urmaliya, Connie Chen
The benefits, limitations and opportunities of preclinical models for neonatal drug development. Disease models & mechanisms 15 (4) (2022)
Lorraine M Posobiec, Susan B Laffan
Dose range finding approach for rodent preweaning juvenile animal studies. Birth defects research 113 (5) (2020)
Dinesh J Stanislaus, Lorraine M Posobiec, Susan B Laffan, Howard M Solomon, Mary K Ziejewski, Elizabeth H Romach
Absence of developmental and reproductive toxicity in animals exposed to dolutegravir. Birth defects research 112 (3) (2019)
Susan B Laffan, Lorraine M Posobiec, Jenny E Uhl, Justin D Vidal
Species Comparison of Postnatal Development of the Female Reproductive System. Birth defects research 110 (3) (2017)